Novel acyl coenzyme A: Diacylglycerol acyltransferase 1 inhibitors - Synthesis and biological activities of N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides

Chemical and Pharmaceutical Bulletin

Volumn 58, Issue 5, 2010, Pages 673-679

  Nakada, Yoshihisa ^a   Ogino, Masaki ^a   Asano, Kouhei ^a   Aoki, Kazuko ^a   Miki, Hiroshi ^a   Yamamoto, Toshihiro ^a   Kato, Koki ^a   Masago, Minori ^a   Tamura, Norikazu ^a   Shimada, Mitsuyuki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Acyl coenzyme A: Diacylglycerol acyltransferase 1 inhibitor; KKAy; Obesity

Indexed keywords

4 ( 3,4 DIETHOXYPHENYL) 4 OXO N 1,1':3',1'' TERPHENYL 5' YL BUTANAMIDE; 4 ( 3,4 DIETHOXYPHENYL) N ( 2,6 DIPHENYLPYRIDIN 4 YL) 4 OXOBUTANAMIDE; 4 ( 3,4 DIETHOXYPHENYL) N ( 4,6 DIPHENYLPYRIDIN 2 YL) 4 OXOBUTANAMIDE; ACYL COENZYME A; ACYLTRANSFERASE INHIBITOR; AMIDE; BENZAMIDE DERIVATIVE; BENZODIOXAN DERIVATIVE; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 1 INHIBITOR; N ( 2,5 DIPHENYL 1,3 THIAZOL 4 YL) 4 ( 3,4 DIETHOXYPHENYL) 4 OXOBUTANAMIDE; N ( 4,5 DIPHENYL 1,3 THIAZOL 2 YL) 4 ( 3,4 DIETHOXYPHENYL) 4 OXOBUTANAMIDE; N ( 5 BENZYL 4 PHENYL 1,3 THIAZOL 2 YL) 4 ( 3 ETHOXYOHENYL) 4 OXOBUTANAMIDE; N ( 5 BENZYL 4 PHENYL 1,3 THIAZOL 2 YL) 4 ( 3,4 DIETHOXYPHENYL) 4 OXOBUTANAMIDE; N ( 5 BENZYL 4 PHENYL 1,3 THIAZOL 2 YL) 4 ( 4 ETHOXYPHENYL) 4 OXOBUTANAMIDE; N ( 5 BENZYL 4 PHENYL 1,3 THIAZOL 2 YL) 4 ( 4,5 DIETHOXY 2 METHYLPHENYL) 4 OXOBUTANAMIDE; N ( 5 BENZYL 4 PHENYL 1,3 THIAZOL 2 YL) 4 OXO 4 ( 4 PROPYLPHENYL)BUTANAMIDE; N ( 5 BENZYL 4 PHENYL 1,3 THIAZOL 2 YL) 4 PHENYL 4 OXOBUTANAMIDE; N ( 5 BENZYL 4 PHENYL 1,3 THIAZOL 2 YL0 4 ( 2,3 DIHYDRO 1,4 BENZODIOXIN 6 YL)BUTANAMIDE; N ( 5 BENZYL 4 PHENYLTHIOPHEN 2 YL) 4 ( 3,4 DIETHOXYPHENYL) 4 OXOBUTANAMIDE; N [ 2 [( 5 BENZYL 4 PHENYL 1,3 THIAZOL 2 YL)AMINO] 2 OXOETHYL] 3,4 DIETHOXYBENZAMIDE; RECOMBINANT DIACYLGLYCEROL ACYLTRANSFERASE 1; RECOMBINANT ENZYME; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; FOOD INTAKE; HUMAN; HUMAN CELL; LIPID DIET; MOUSE; NONHUMAN; OBESITY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

AMIDES; ANIMALS; DIACYLGLYCEROL O-ACYLTRANSFERASE; DRUG DESIGN; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 77951738511     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.58.673     Document Type: Article

References (20)

1. Chen H. C., Farese R. V. Jr., Trends Cardiovasc. Med., 10, 188-192 (2000).
2. Cases S., Smith S. J., Zheng Y., Myers H. M., Lear S. R., Sande E., Novak S., Collins C., Welch C. B., Lusis A. J., Erickson S. K., Farese R. V. Jr., Proc. Natl. Acad. Sci. U.S.A., 95, 13018-13023 (1998).
3. Cases S., Stone S. J., Zhou P., Yen E., Tow B., Lardizabal K. D., Voelker T., Farese R. V. Jr., J. Biol. Chem., 276, 38870-38876 (2001).
4. Smith S. J., Cases S., Jensen D. R., Chen H. C., Sande E., Tow B., Sanan D. A., Raber J., Eckel R. H., Farese R. V. Jr., Nat. Genet., 25, 87-90 (2000).
5. Chen H. C., Smith S. J., Ladha Z., Jensen D. R., Ferreira L. D., Pulawa L. K., McGuire J. G., Pitas R. E., Eckel R. H., Farese R. V. Jr., J. Clin. Invest., 109, 1049-1055 (2002).
6. Chen H. C., Stone S. J., Zhou P., Buhman K. K., Farese R. V. Jr., Diabetes, 51, 3189-3195 (2002).
7. Zhao G., Souers A. J., Voorbach M., Falls H. D., Droz B., Brodjian S., Lau Y. Y., Iyengar R. R., Gao J., Judd A. S., Wagaw S. H., Ravn M. M., Engstrom K. M., Lynch J. K., Mulhern M. M., Freeman J., Dayton B. D., Wang X., Grihalde N., Fry D., Beno D. W. A., Marsh K. C., Su Z., Diaz G. J., Collins C. A., Sham H., Reilly R. M., Brune M. E., Kym P. R., J. Med. Chem., 51, 380-383 (2008).
8. King A. J., Segreti J. A., Larson K. J., Souers A. J., Kym P. R., J. Pharm. Exp. Ther., 330, 526-531 (2009).
9. Birch A. M., Birtles S., Buckett L. K., Kemmitt P. D., Smith G. J., Smith T. J. D., Turnbull A. V., Wang S. J. Y., J. Med. Chem., 52, 1558-1568 (2009).
10. 12j, 12l: Park C.-M., Sun C., Olejniczak E. T., Wilson A. E., Meadows R. P., Betz S. F., Elmore S. W., Fesik S. W., Bioorg. Med. Chem. Lett., 15, 771-776 (2005);
11. Kurkjy R. P., Brown E. V., J. Am. Chem. Soc., 74, 6260 (1952).
12. 12m: Buchstaller H.-P., Siebert C. D., Lyssy R. H., Frank I., Duran A., Gottschlich R., Noe C. R., Monatsh. Chem., 132, 279 (2001);
13. Luetjens H., Zickgraf A., Figler H., Linden J., Olsson R. A., Scammells P. J., J. Med. Chem., 46, 1870-1877 (2003).
14. Imoto H., Sugiyama Y., Kimura H., Momose Y., Chem. Pharm. Bull., 51, 138-151 (2003).
15. Inanaga J., Hirata K., Saeki H., Katsuki T., Yamaguchi M., Bull. Chem. Soc. Jpn., 52, 1989 (1979).
16. Compound 12k was prepared as described in Kerdesky F. A. J., Holms J. H., Moore J. L., Bell R. L., Dyer R. D., Carter G. W., Brooks D. W., J. Med. Chem., 34, 2158-2165 (1991).
17. Compound 12o was prepared as described in J. A. Van Allan, S. Chie Chang, G. A. Reynolds, J. Hetrocycl. Chem., 11, 195-198 (1974).
18. Zecher W., Kröhnke F., Chem. Ber., 94, 698-704 (1961).
19. Compound 12n was prepared as described in Ozasa S., Fujioka Y., Kikutake J., Ibuki E., Chem. Pharm. Bull., 31, 1572-1581 (1983).
20. Yamamoto T., Yamaguchi H., Miki H., Shimada M., Nakada Y., Ogino M., Asano K., Aoki K., Tamura N., Masago M., Kato K. in preparation.